220 related articles for article (PubMed ID: 23952194)
1. Bevacizumab for the treatment of glioblastoma.
Chowdhary S; Chamberlain M
Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
[TBL] [Abstract][Full Text] [Related]
2. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC
Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
[TBL] [Abstract][Full Text] [Related]
3. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
4. [Anti-angiogenic strategies in glioblastoma].
Guillamo JS
Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
6. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab as first-line therapy for glioblastoma.
Piccioni D; Lai A; Nghiemphu P; Cloughesy T
Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
[TBL] [Abstract][Full Text] [Related]
8. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
Khasraw M; Ameratunga M; Grommes C
Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
[TBL] [Abstract][Full Text] [Related]
10. The future of antiangiogenic treatment in glioblastoma.
Chinot OL; Reardon DA
Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
[TBL] [Abstract][Full Text] [Related]
11. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
14. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic therapy for malignant glioma].
Nagane M
Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
18. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
19. Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
Walbert T; Mikkelsen T
Expert Rev Neurother; 2011 Apr; 11(4):509-18. PubMed ID: 21469924
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]